Drug profile · INN
acitretin
NEOTIGASON
acitretin (NEOTIGASON) is a retinoid receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — acitretin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
acitretin (NEOTIGASON) is a retinoid receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Retinoid receptor agonist
Primary target: Retinoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is acitretin?
acitretin (NEOTIGASON) is a retinoid receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for acitretin?
NEOTIGASON is a marketed brand name for acitretin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of acitretin?
acitretin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.